Abstract
Targeted drug delivery systems (TDDS) represent one of the most promising advancements in cancer treatment. These systems aim to improve the therapeutic efficacy of anticancer drugs while minimizing their toxicity to healthy tissues. Recent developments in TDDS have led to the design of nanoparticles, conjugates, and biologically active agents that enhance the precision of drug delivery. This article reviews the latest progress in targeted drug delivery for cancer treatment, emphasizing the types of nanoparticles used, their mechanisms, clinical applications, and challenges faced in translating these systems from laboratory research to clinical settings. Through a deeper understanding of tumor biology, researchers have refined strategies to achieve selective and controlled drug release, potentially revolutionizing cancer therapy.
All articles published in the American Journal of Pharmaceutics are open access and licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows users to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given, a link to the license must be provided, and any changes must be indicated.
-
Authors retain full copyright of their work.
-
The journal does not restrict reuse of content, provided proper citation of the original publication is made.